Eli Lilly And Co logo

LLY - Eli Lilly And Co Share Price

$204.89 1.1  0.5%

Last Trade - 26/02/21

Large Cap
Market Cap £140.95bn
Enterprise Value £150.35bn
Revenue £17.61bn
Position in Universe 47th / 6715
Unlock LLY Revenue
Relative Strength (%)
1m -2.37%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.01%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
19,959 21,222 19,974 21,493 22,320 24,540 26,108 27,274 +4.2%
+15.8 -9.3 +112.2 -12.7 +6.2 +33.9 +4.24 +9.53
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, EliLilly And Co revenues increased 10% to $24.54B. Net incomebefore extraordinary items increased 34% to $6.19B.Revenues reflect U.S. segment increase of 12% to $14.23B,Europe segment increase of 11% to $4.19B. Net incomebenefited from Other income (expense) increase from $344.6Mto $1.25B (income), Impairment of Fixed Assets decreasefrom $497.8M (expense) to $20M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for LLY
Graphical History


LLY Revenue Unlock LLY Revenue

Net Income

LLY Net Income Unlock LLY Revenue

Normalised EPS

LLY Normalised EPS Unlock LLY Revenue

PE Ratio Range

LLY PE Ratio Range Unlock LLY Revenue

Dividend Yield Range

LLY Dividend Yield Range Unlock LLY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LLY EPS Forecasts Unlock LLY Revenue
Profile Summary

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated January 17, 1901
Public Since July 9, 1970
No. of Shareholders: 21,650
No. of Employees: 35,000
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange New York Stock Exchange
Shares in Issue 958,425,693
Free Float (0.0%)
Eligible for
LLY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for LLY
Upcoming Events for LLY
Tuesday 27th April, 2021
Q1 2021 Eli Lilly and Co Earnings Release
Tuesday 27th April, 2021
Q1 2021 Eli Lilly and Co Earnings Call
Frequently Asked Questions for Eli Lilly and Co
What is the Eli Lilly and Co share price?

As of 26/02/21, shares in Eli Lilly and Co are trading at $204.89, giving the company a market capitalisation of £140.95bn. This share price information is delayed by 15 minutes.

How has the Eli Lilly and Co share price performed this year?

Shares in Eli Lilly and Co are currently trading at $204.89 and the price has moved by 58.6% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Eli Lilly and Co price has moved by 22.35% over the past year.

What are the analyst and broker recommendations for Eli Lilly and Co?

Of the analysts with advisory recommendations for Eli Lilly and Co, there are there are currently 3 "buy" , 10 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Eli Lilly and Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Eli Lilly and Co next release its financial results?

Eli Lilly and Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Eli Lilly and Co dividend yield?

The Eli Lilly and Co dividend yield is 1.44% based on the trailing twelve month period.

Does Eli Lilly and Co pay a dividend?

Last year, Eli Lilly and Co paid a total dividend of 2.96, and it currently has a trailing dividend yield of 1.44%. Looking ahead, Eli Lilly and Co has not announced an ex-dividend date yet and the next dividend pay date is 2021-03-10.

When does Eli Lilly and Co next pay dividends?

Eli Lilly and Co has yet to annouce their ex-dividend date and the next dividend pay date is 2021-03-10. The historic dividend yield on Eli Lilly and Co shares is currently 1.44%.

How do I buy Eli Lilly and Co shares?

To buy shares in Eli Lilly and Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Eli Lilly and Co?

Shares in Eli Lilly and Co are currently trading at $204.89, giving the company a market capitalisation of £140.95bn.

Where are Eli Lilly and Co shares listed? Where are Eli Lilly and Co shares listed?

Here are the trading details for Eli Lilly and Co:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: LLY
What kind of share is Eli Lilly and Co?

Based on an overall assessment of its quality, value and momentum, Eli Lilly and Co is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Eli Lilly and Co share price forecast 2021?

Shares in Eli Lilly and Co are currently priced at $204.89. At that level they are trading at 18.81% premium to the analyst consensus target price of 0.00.

Analysts covering Eli Lilly and Co currently have a consensus Earnings Per Share (EPS) forecast of 7.958 for the next financial year.

How can I tell whether the Eli Lilly and Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eli Lilly and Co. Over the past six months, the relative strength of its shares against the market has been 27.11%. At the current price of $204.89, shares in Eli Lilly and Co are trading at 27.32% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Eli Lilly and Co PE Ratio?

The Eli Lilly and Co PE ratio based on its reported earnings over the past 12 months is 26.84. The shares are currently trading at $204.89.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Eli Lilly and Co?

Eli Lilly and Co's management team is headed by:

Raul Alvarez - IND
Stephen Fry - SVP
David Ricks - CHM
Katherine Baicker - IND
Melissa Barnes - SVP
Juan Luciano - LED
Carolyn Bertozzi - IND
Johna Norton - SVP
Aarti Shah - SVP
Daniel Skovronsky - SVP
Patrik Jonsson - SVP
Anat Hakim - SVP
Michael Mason - SVP
Gabrielle Sulzberger - DRC
Anat Ashkenazi - CFO
Who are the major shareholders of Eli Lilly and Co?

Here are the top five shareholders of Eli Lilly and Co based on the size of their shareholding:

Lilly Endowment, Inc. Investment Advisor
Percentage owned: 11.53% (110.5m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.16% (68.7m shares)
PNC Wealth Management Investment Advisor
Percentage owned: 5.36% (51.4m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.01% (38.4m shares)
PRIMECAP Management Company Investment Advisor
Percentage owned: 3.84% (36.8m shares)
Similar to LLY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.